Your browser doesn't support javascript.
loading
Strategies for the modulation of phase II metabolism in a series of PKCε inhibitors.
Clemens, Jeremy J; Coon, Timothy; Busch, Brett B; Asgian, Juliana L; Hudson, Sarah; Termin, Andreas; Flores, Tina B; Tran, Dao; Chiang, Peggy; Sperry, Sam; Gross, Ray; Abt, Jeffrey; Heim, Roger; Lechner, Sandra; Twin, Heather; Studley, John; Brenchley, Guy; Collier, Philip N; Pierard, Francoise; Miller, Andrew; Mak, Chau; Dvornikovs, Vadims; Jimenez, Juan-Miguel; Stamos, Dean.
Afiliação
  • Clemens JJ; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States. Electronic address: jeremy_clemens@vrtx.com.
  • Coon T; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Busch BB; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Asgian JL; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Hudson S; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Termin A; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Flores TB; Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Tran D; Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Chiang P; Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Sperry S; Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Gross R; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Abt J; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Heim R; Department of Biology, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Lechner S; Department of Biology, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
  • Twin H; Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd, 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom.
  • Studley J; Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd, 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom.
  • Brenchley G; Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd, 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom.
  • Collier PN; Department of Medicinal Chemistry, Vertex Pharmaceuticals, 50 Northern Avenue, Boston, MA 02210, United States.
  • Pierard F; Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd, 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom.
  • Miller A; Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd, 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom.
  • Mak C; Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd, 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom.
  • Dvornikovs V; Department of Medicinal Chemistry, Vertex Pharmaceuticals, 50 Northern Avenue, Boston, MA 02210, United States.
  • Jimenez JM; Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd, 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW, United Kingdom.
  • Stamos D; Department of Chemistry and Drug Innovation, Vertex Pharmaceuticals, 11010 Torreyana Road, San Diego, CA 92121, United States.
Bioorg Med Chem Lett ; 24(15): 3398-402, 2014 Aug 01.
Article em En | MEDLINE | ID: mdl-24939756
Extensive phase II metabolism of an advanced PKCε inhibitor resulted in sub-optimal pharmacokinetics in rat marked by elevated clearance. Synthesis of the O-glucuronide metabolite as a standard was followed by three distinct strategies to specifically temper phase II metabolic degradation of the parent molecule. In this study, it was determined that the introduction of proximal polarity to the primary alcohol generally curbed O-glucuronidation and improved PK and physical chemical properties while maintaining potency against the target. Utilization of a Jacobsen hydrolytic kinetic resolution to obtain optically enriched final compounds is also discussed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glucuronídeos / Inibidores de Proteínas Quinases / Proteína Quinase C-épsilon Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glucuronídeos / Inibidores de Proteínas Quinases / Proteína Quinase C-épsilon Idioma: En Ano de publicação: 2014 Tipo de documento: Article